Item 8.01. Other Events.

On July 19, 2022, Brickell Biotech, Inc. (the "Company") received formal notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5450(a)(1) and, accordingly, the scheduled hearing has been canceled and the Company's common stock will continue to be listed and traded on Nasdaq.

As previously disclosed, on June 14, 2022, Nasdaq notified the Company that, based upon its continued non-compliance with the minimum closing bid price requirement as of June 13, 2022, the Company's common stock was subject to delisting from Nasdaq, unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company timely requested the hearing, which request stayed any further delisting action. The hearing has been canceled.

A copy of the press release that discusses this matter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



99.1        Press release issued by Brickell Biotech, Inc. on July 20, 2022

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses